This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Odenike, O. M. Articles by Stock, W. Search for Related Content PubMed PubMed Citation Articles by Odenike, O. M. Articles by Stock, W.

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

Authors' Affiliations: ¹ Medicine and ² Health Studies, University of Chicago, Chicago, Illinois, ³ Pathology and Medicine, Loyola University, Maywood, Illinois; ⁴ Medicine, Vanderbilt University, Nashville, Illinois, ⁵ Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; and ⁶ National Cancer Institute, Bethesda, Maryland

Requests for reprints: Olatoyosi M. Odenike, Section of Hematology/Oncology, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, IL. Phone: 773-702-3354; Fax: 773-702-0963; E-mail: todenike{at}medicine.bsd.uchicago.edu.

Purpose: Recruitment of histone deacetylases (HDAC) is a mechanism of transcriptional repression implicated in the differentiation block in acute myeloid leukemia (AML). We hypothesized that the HDAC inhibitor romidepsin could cause transcriptional derepression, up-regulation of specific target genes in AML, and differentiation of the leukemic clone. The primary objectives of the study were to evaluate the safety and efficacy of romidepsin in advanced AML.

Experimental Design: Twenty patients were stratified into cohort A or B based on the absence or presence of chromosomal abnormalities known to recruit HDACs, including those involving core binding factor (CBF). Romidepsin was administered i.v. at 13 mg/m²/d on days 1, 8, and 15 of a 28-day cycle. Pharmacodynamic endpoints were evaluated at serial time points.

Results: Common adverse effects noted were grade 1 to 2 nausea, anorexia, and fatigue. No objective evidence of antileukemic activity was seen in cohort A. In cohort B, although there were no clinical responses by standard criteria, antileukemic activity was observed in 5 of 7 patients. Two patients had clearance of bone marrow blasts and 3 patients had a >50% decrease in bone marrow blasts. Furthermore, in cohort B, at 24 h, there was a significant increase in MDR1 (P = 0.005), p15 (P = 0.01), and p14 (P < 0.0001) expression. In cohort A, although there was a trend toward up-regulation of MDR1, p15, and p14 expression, these changes were not statistically significant.

Conclusion: Romidepsin has differential antileukemic and molecular activity in CBF AML. Development of this agent in CBF AML should focus on combinations that target related mechanisms of gene silencing such as DNA methylation.

This article has been cited by other articles:

				H. Matsubara, M. Watanabe, T. Imai, Y. Yui, Y. Mizushima, Y. Hiraumi, Y. Kamitsuji, K.-i. Watanabe, K. Nishijo, J. Toguchida, et al. Involvement of Extracellular Signal-Regulated Kinase Activation in Human Osteosarcoma Cell Resistance to the Histone Deacetylase Inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone] J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 839 - 848. [Abstract] [Full Text] [PDF]